newsfilter
← Latest News
Business Wire·

Sage Therapeutics Announces Second Quarter 2025 Financial Results

Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter Previously